• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Onymos and Vapotherm Announce Partnership to Create an End-to-End Internet of Medical Things Solution (IoMT)

    3/20/24 8:30:00 AM ET
    $VAPO
    Medical/Dental Instruments
    Health Care
    Get the next $VAPO alert in real time by email

    Partnership enables Vapotherm to build a robust and secure solution 80% faster than the standard development timeline to meet data visualization and device management goals for HVT® 2.0 and future Home system

    SAN FRANCISCO, March 20, 2024 /PRNewswire/ -- Onymos, developer of the world's first Features-as-a-Service platform, and Vapotherm, Inc. (OTCQX:VAPO), ("Vapotherm"), a global medical technology company whose proprietary high-velocity therapy® products treat patients of all ages suffering from respiratory distress, today announced the formation of a development and commercialization partnership. This partnership will help Vapotherm create a unique respiratory digital platform to meet its data visualization and device management goals for the Vapotherm HVT® 2.0 system in the acute care space as well as for future products in the home.

    Onymos (PRNewsfoto/Onymos)

    Through the Onymos Features-as-a-Service platform, Vapotherm accesses Onymos' suite of Internet of Things (IoT) features — including Onymos Edge, Onymos Access, and Onymos DataStore — to build a secure end-to-end solution to connect the HVT 2.0 fleet with the cloud. It consists of a GoLang-based "Gateway" application, an Angular web dashboard for remote device management, and cloud storage for patient data. The solution is currently undergoing beta testing with select hospitals.

    The HVT 2.0 system currently uses Vapotherm's revolutionary high-velocity therapy® and has a large, intuitive touchscreen to display relevant clinical information at a distance (flow, FiO2, temperature, safety alarms, event log etc.). Connectivity provides clinically relevant information remotely to help medical teams make informed and confident decisions quickly.

    "We continually look to provide our customers with innovative solutions to improve patient outcomes as evidenced by our recent HVT 2.0 launch and future home offerings. We believe that by adopting Onymos' suite of IoT features into these products it will help medical teams make informed decisions quickly to help treat their patients and improve outcomes at a lower cost. This is huge for understaffed hospitals especially. It's an honor to help our customers and to partner with Onymos to make our connected cloud solutions a reality – one that continues to enhance and adjust according to physician feedback and needs," said Vapotherm's Chief Technology Officer, Brian Lawrence.

    "We are proud to work alongside Vapotherm to help the company realize its data visualization and device management goals for the HVT 2.0 system and future home product," said Shiva Nathan, Founder and CEO of Onymos. "By leveraging multiple facets of our Features-as-a-Service platform, we are able to develop an extensive Internet of Medical Things solution that is both SOC 2 and HIPAA compliant 80 percent faster than the standard development timeline."

    The Onymos Features-as-a-Service platform is a pro-code platform that enables companies and organizations — such as medical device manufacturers, pharmaceutical companies, retailers, and education institutions — to achieve unmatched speed, quality, and value in their web, mobile, and IoT application development and innovation. It has over 20 foundational app features and can be easily added to new or existing applications. The Onymos platform includes the UI/UX, security, help with compliance requirements, underlying logic that runs on the device, the server-side functions and integrations that process and store data in the cloud, and continuous updates. The Onymos platform also supports many of the other most popular frameworks for web and mobile application development.

    For more information on Onymos, its Features-as-a-Service platform, or how it can help your company realize its IoT or IoMT goals, visit Onymos.com. 

    About Vapotherm

    Vapotherm, Inc. (OTCQX:VAPO) is a publicly traded developer and manufacturer of advanced respiratory technology based in Exeter, New Hampshire, USA. The Company develops innovative, comfortable, non-invasive technologies for respiratory support of patients with chronic or acute breathing disorders. Over 4.2 million patients have been treated with the use of Vapotherm high-velocity therapy® systems. For more information, visit https://vapotherm.com/. 

    Vapotherm high-velocity therapy is mask-free non-invasive ventilatory support and is a front-line tool for relieving respiratory distress—including hypercapnia, hypoxemia, and dyspnea. It allows for the fast, safe treatment of undifferentiated respiratory distress with one tool. The HVT 2.0 and Precision Flow systems' mask-free interface delivers optimally conditioned breathing gases, making it comfortable for patients and reducing the risks and care complexities associated with mask therapies. While being treated, patients can talk, eat, drink and take oral medication.

    About Onymos

    Onymos is the developer of the world's first Features-as-a-Service platform. Our more than 20 foundational app features enable enterprises to build innovative and differentiated apps with unmatched speed, quality, and value. Onymos is trusted by top brands, including Albertsons, CVS, and Walmart. For more information, visit Onymos.com, and join the conversation on LinkedIn and X (Twitter).

    Media Contact

    Maggie Markert

    Zer0 to 5ive for Onymos

    [email protected] 

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/onymos-and-vapotherm-announce-partnership-to-create-an-end-to-end-internet-of-medical-things-solution-iomt-302093848.html

    SOURCE Onymos

    Get the next $VAPO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $VAPO

    DatePrice TargetRatingAnalyst
    5/6/2022$12.00 → $5.00Buy → Hold
    Canaccord Genuity
    4/7/2022$23.00 → $8.00Overweight → Underweight
    Piper Sandler
    More analyst ratings

    $VAPO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Vapotherm Announces Closing of Merger

      EXETER, N.H., Sept. 20, 2024 /PRNewswire/ -- Vapotherm, Inc. (OTCQX:VAPO), ("Vapotherm" or the "Company"), announced today that it has closed its merger with a newly-formed entity organized and funded by an affiliate of Perceptive Advisors, LLC. On June 17, 2024, the Company announced that it had signed a definitive agreement and plan of merger with a newly-formed entity organized and funded by an affiliate of Perceptive Advisors, LLC, a leading health care investment firm ("Perceptive"), and its Perceptive Discovery Fund. Concurrently with the entry into the definitive agreem

      9/20/24 10:33:00 AM ET
      $VAPO
      Medical/Dental Instruments
      Health Care
    • Vapotherm Reports Second Quarter 2024 Financial Results

      EXETER, N.H., Aug. 12, 2024 /PRNewswire/ -- Vapotherm, Inc. (OTCQX:VAPO), ("Vapotherm" or the "Company"), today announced second quarter 2024 financial results and related highlights. Second Quarter 2024 Financial Results and Related Highlights Net revenue for the second quarter of 2024 was $16.9 million, an increase of 5.3% as compared to the second quarter of 2023Disposables revenue increased by 13.9% as compared to the second quarter of 2023U.S. disposables revenue increased by 25.9% as compared to the second quarter of 2023Gross margin in the second quarter of 2024 was 49.

      8/12/24 5:15:00 PM ET
      $VAPO
      Medical/Dental Instruments
      Health Care
    • Vapotherm Enters Into Definitive Merger Agreement; Transaction Would Result In Company Going Private

      EXETER, N.H., June 17, 2024 /PRNewswire/ -- Vapotherm, Inc. (OTCQX:VAPO), ("Vapotherm" or the "Company"), announced today that it has signed a definitive merger agreement with a newly-formed entity organized and funded by an affiliate of Perceptive Advisors, LLC, a leading health care investment firm ("Perceptive"), and its Perceptive Discovery Fund.  Concurrently with the entry into the definitive merger agreement, our existing lender, investment affiliates managed by SLR Capital Partners ("SLR") have agreed to convert approximately $81.0 million of term debt into preferred equity of the newly-formed entity, and Perceptive will invest $50.0 million of new preferred equity capital into the b

      6/17/24 6:55:00 AM ET
      $VAPO
      Medical/Dental Instruments
      Health Care

    $VAPO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Arnerich Anthony L. bought $117,337 worth of shares (37,750 units at $3.11), increasing direct ownership by 263% to 24,509 units (SEC Form 4) (Amendment)

      4/A - VAPOTHERM INC (0001253176) (Issuer)

      10/4/23 4:11:34 PM ET
      $VAPO
      Medical/Dental Instruments
      Health Care

    $VAPO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Vapotherm downgraded by Canaccord Genuity with a new price target

      Canaccord Genuity downgraded Vapotherm from Buy to Hold and set a new price target of $5.00 from $12.00 previously

      5/6/22 7:28:09 AM ET
      $VAPO
      Medical/Dental Instruments
      Health Care
    • Vapotherm downgraded by Piper Sandler with a new price target

      Piper Sandler downgraded Vapotherm from Overweight to Underweight and set a new price target of $8.00 from $23.00 previously

      4/7/22 7:25:32 AM ET
      $VAPO
      Medical/Dental Instruments
      Health Care
    • Piper Sandler reiterated coverage on Vapotherm with a new price target

      Piper Sandler reiterated coverage of Vapotherm with a rating of Overweight and set a new price target of $36.00 from $39.00 previously

      2/25/21 7:36:13 AM ET
      $VAPO
      Medical/Dental Instruments
      Health Care

    $VAPO
    Leadership Updates

    Live Leadership Updates

    See more
    • Perimeter Medical Imaging AI Strengthens Leadership Team with Appointment of Experienced MedTech Executive, Adam Hodges, as Vice President, Sales and Marketing

      TORONTO and DALLAS, Sept. 8, 2023 /PRNewswire/ - Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTC: PYNKF) (FSE: 4PC) ("Perimeter" or the "Company") – a commercial-stage medical technology company – today announced the appointment of experienced medtech sales executive, Adam Hodges, as its Vice President, Sales and Marketing, effective immediately. Adrian Mendes, Perimeter's Chief Executive Officer stated, "I am excited to welcome Adam to the Perimeter team as our senior leader responsible for the strategy and execution of our sales-related goals. Adam's extensive medtech b

      9/8/23 8:30:00 AM ET
      $IART
      $VAPO
      Medical/Dental Instruments
      Health Care
    • Eargo Announces Strategic Additions to Board of Directors Following Patient Square Capital Becoming New Majority Shareholder

      SAN JOSE, Calif., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Eargo, Inc. ("Eargo" or the "Company") (NASDAQ:EAR), a medical device company on a mission to improve the quality of life for people with hearing loss, today announced the appointments of several new directors following the closing of the Company's rights offering as previously announced on November 29, 2022. Patient Square Capital became the Company's majority owner upon closing of the rights offering and conversion of Patient Square's senior secured convertible notes per its investment in June 2022. As previously announced, following the completion of the rights offering, Patient Square has the right to nominate a number of directors t

      12/7/22 4:05:00 PM ET
      $EAR
      $ITGR
      $VAPO
      Medical Specialities
      Health Care
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Medical/Dental Instruments

    $VAPO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Arnerich Anthony L. returned $344,305 worth of shares to the company (232,993 units at $1.48), closing all direct ownership in the company (SEC Form 4)

      4 - VAPOTHERM INC (0001253176) (Issuer)

      9/24/24 5:01:08 PM ET
      $VAPO
      Medical/Dental Instruments
      Health Care
    • President and CEO Army Joseph returned $43,419 worth of shares to the company (452,698 units at $0.10), closing all direct ownership in the company (SEC Form 4)

      4 - VAPOTHERM INC (0001253176) (Issuer)

      9/24/24 4:43:19 PM ET
      $VAPO
      Medical/Dental Instruments
      Health Care
    • SVP & Chief Financial Officer Landry John returned $51,982 worth of shares to the company (71,661 units at $0.73), closing all direct ownership in the company (SEC Form 4)

      4 - VAPOTHERM INC (0001253176) (Issuer)

      9/24/24 4:14:26 PM ET
      $VAPO
      Medical/Dental Instruments
      Health Care

    $VAPO
    Financials

    Live finance-specific insights

    See more
    • Vapotherm To Report Second Quarter 2023 Financial Results

      Vapotherm, Inc. (NYSE:VAPO), ("Vapotherm" or the "Company"), today announced that it will release financial results for the second quarter of 2023 after the close of trading on Tuesday, August 8, 2023. Vapotherm's management team will host a conference call beginning at 4:30 p.m. ET to discuss the financial results and recent business developments. To listen to the conference call on your telephone, please dial +1 (888) 330-2391 for U.S. callers, or +1 (240) 789-2702 for international callers, approximately ten minutes prior to the start time and reference conference code 6585549. To listen to a live webcast, please visit the Investors section of the Vapotherm website at: http://investors

      7/25/23 4:30:00 PM ET
      $VAPO
      Medical/Dental Instruments
      Health Care
    • Vapotherm Reports First Quarter 2023 Financial Results

      Vapotherm, Inc. (NYSE:VAPO), ("Vapotherm" or the "Company"), today announced first quarter 2023 financial results. First Quarter 2023 Summary and Highlights Total revenue for the first quarter of 2023 was $17.7 million Capital revenue increased by 28% as compared to the fourth quarter of 2022 due to strong HVT 2.0 sales Disposables revenue decreased by 12% as compared to the fourth quarter of 2022 due to the timing of the US flu season Gross margin in the first quarter of 2023 was 35.0% Gross margin increased by 750 basis points over the fourth quarter of 2022 due to initial benefits from the transition of operations to Mexico For the first quarter of 2023, GAAP oper

      5/3/23 4:10:00 PM ET
      $VAPO
      Medical/Dental Instruments
      Health Care
    • Vapotherm To Report First Quarter 2023 Financial Results

      Vapotherm, Inc. (NYSE:VAPO), ("Vapotherm" or the "Company"), today announced that it will release financial results for the first quarter of 2023 after the close of trading on Wednesday, May 3, 2023. Vapotherm's management team will host a conference call beginning at 4:30 p.m. ET to discuss the financial results and recent business developments. To listen to the conference call on your telephone, please dial +1 (888) 330-2391 for U.S. callers, or +1 (240) 789-2702 for international callers, approximately ten minutes prior to the start time and reference conference code 6585549. To listen to a live webcast, please visit the Investors section of the Vapotherm website at: http://investors.v

      4/27/23 4:30:00 PM ET
      $VAPO
      Medical/Dental Instruments
      Health Care

    $VAPO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Vapotherm Inc.

      SC 13D/A - VAPOTHERM INC (0001253176) (Subject)

      9/24/24 7:04:57 PM ET
      $VAPO
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Vapotherm Inc.

      SC 13D/A - VAPOTHERM INC (0001253176) (Subject)

      9/20/24 10:32:59 AM ET
      $VAPO
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Vapotherm Inc.

      SC 13G - VAPOTHERM INC (0001253176) (Subject)

      7/18/24 7:24:17 PM ET
      $VAPO
      Medical/Dental Instruments
      Health Care

    $VAPO
    SEC Filings

    See more
    • SEC Form 15-12G filed by Vapotherm Inc.

      15-12G - VAPOTHERM INC (0001253176) (Filer)

      9/25/24 11:32:00 AM ET
      $VAPO
      Medical/Dental Instruments
      Health Care
    • SEC Form EFFECT filed by Vapotherm Inc.

      EFFECT - VAPOTHERM INC (0001253176) (Filer)

      9/25/24 12:15:03 AM ET
      $VAPO
      Medical/Dental Instruments
      Health Care
    • SEC Form EFFECT filed by Vapotherm Inc.

      EFFECT - VAPOTHERM INC (0001253176) (Filer)

      9/25/24 12:15:04 AM ET
      $VAPO
      Medical/Dental Instruments
      Health Care